Viewing Opinion | StockChase

Bristol Myers Squibb (BMY-N) opinion on 2016-12-13

Last Price Recorded: 62.8100 on 2018-01-15

ON STOCKCHASE SINCE Apr 2001

biotechnology/pharmaceutical
biotechnology/pharmaceutical
COMMENT

David Burrows
Bristol Myers Squibb was $57.170 at time of opinion
Owned : Unknown

The pharma group went out of favour 3-4 months ago. That became a source of funds for people to rotate into other industries. We are now heading into year-end, with a market where buying is broadening out into more and more sectors. The healthcare sector seems to be catching a little bit of a bid, it is improving. He would describe the sector as being “neutral, to a little better”. Within the sector, this company has had some disappointment recently. He would prefer something like a Merck (MRK-N), which sets up better, and has a broad-based portfolio of products.

BULLISH

All opinions for BMY-N (133)

28 BUY
21 COMMENT
30 DON'T BUY
7 HOLD
2 PARTIAL SELL
13 PAST TOP PICK
3 SELL
1 SELL ON STRENGTH
22 TOP PICK
3 WATCH
3 WEAK BUY
View All

More experts covering BMY-N

SAVE
Add BMY-N to Watch List

All opinions for BMY-N (133)

28 BUY
21 COMMENT
30 DON'T BUY
7 HOLD
2 PARTIAL SELL
13 PAST TOP PICK
3 SELL
1 SELL ON STRENGTH
22 TOP PICK
3 WATCH
3 WEAK BUY
View All

More experts covering BMY-N

SAVE
Add BMY-N to Watch List

Last 60 Days Opinions

PAST TOP PICK
6 days ago
BUY
2 weeks ago
Post Comment

1 Comment

Ron

December 13th 2016 at 5:55pm

What might be worth looking at is TEVA-N. It has been beaten up big time


You must be logged in to comment.

Successfully Saved Company